Syngene International wins CMO Leadership Awards
Syngene was successfully rated across the six categories - Capabilities, Compatibility, Expertise, Quality, Reliability and Service – that were used to gauge the eventual winner. For the 2019 CMO Leadership Awards, Life Science Leader teamed up with Industry Standard Research (ISR) to assess more than 120 contract manufacturers and determine the award recipients.
Bengaluru: Syngene International Ltd., an innovation-focused global discovery, development and manufacturing organization, announced that it has won the CMO Leadership Awards presented by Life Science Leader magazine. This award was announced on the sidelines of the DCAT Week held from March 18-21, 2019 in New York City.
The CMO Leadership Awards was instituted by Life Science Leader magazine in 2011 to recognize leading contract manufacturing organizations globally. The magazine caters to the life sciences industry and provides insight into areas such as research and development, manufacturing, regulatory landscape, clinical trials.
Also Read: Biocon sells 1.88 per cent stake in Syngene for Rs 230 crore
Syngene was successfully rated across the six categories - Capabilities, Compatibility, Expertise, Quality, Reliability and Service – that were used to gauge the eventual winner. For the 2019 CMO Leadership Awards, Life Science Leader teamed up with Industry Standard Research (ISR) to assess more than 120 contract manufacturers and determine the award recipients.
Jonathan Hunt, Chief Executive Officer, Syngene International, said, “We are delighted to receive the CMO Leadership Award. This award is a recognition of the exemplary work done by our staff to deliver truly excellent service to our growing global customer base. Syngene’s track record of delivering innovation at the highest global quality standards is a real differentiator."
"Our investments in expanded manufacturing capacities, for both small and large molecules, ensure we can be a ‘one-stop’ solution provider for our clients across all stages of the drug discovery, development and manufacturing value chain,” added Hunt.
Also Read: Syngene International draws up 102 million dollars spending programme
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd